

Breadcrumb

Entity Print



Fabio Ciceri
ALWP Chair
Italy

Major achievements

The ALWP continues its activities through the active engagement of its members and the support of the EBMT staff. The collaborative efforts within the Working Party have enabled the successful development and completion of several important studies during the past year, addressing clinically relevant questions in the field of HCT for patients with acute leukaemia.

A number of studies have focused on donor selection strategies, including comparative studies evaluating outcomes following transplantation from younger haploidentical donors versus older matched unrelated donors, as well as donor selection in elderly patients. Additional studies have evaluated the prognostic impact of cytogenetic and molecular risk stratification, including outcomes according to the ELN 2022 adverse cytogenetic subgroups and the clinical relevance of specific genetic categories.

Further studies have explored strategies aimed at optimizing transplant approaches through risk-adapted methodologies. These include studies assessing cytogenetic- and molecular risk–driven conditioning intensity and analyses evaluating the impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide–based GVHD prophylaxis. In addition, analyses on evolving treatment practices, including the increasing use of pharmacologic maintenance therapy following allo-HCT in patients with AML.

Collectively, these and many other studies contribute to an expanding portfolio of ALWP research. The contributions of ALWP members, study investigators, and the EBMT staff are gratefully acknowledged. The ALWP remains committed to fostering collaborative research within the EBMT network with the aim of further advancing the field of transplantation in acute leukaemia.

Principal research studies

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic
Principal investigator
Ali Bazarbachi

Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT
Study type
Retrospective Studies
Diseases
Acute Lymphatic Leukaemia (ALL)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic
Principal investigator
Dr. Juan Montoro
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT
Study type
Retrospective Studies
Diseases
Acute Myeloid Leukaemia (AML)
Group
Acute Leukemia Working Party (ALWP)
Type of treatment
Allogeneic
Principal investigator
Dr. Arnon Nagler

Key publications

2025
Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Jaime Sanz
Journal

Haematologica.
2025
Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Yishan Ye
Journal
Am J Hematol.
2025
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Group
Acute Leukemia Working Party (ALWP)
Global Committee
1st listed author
Lin Li
Journal
Haematologica.
2025
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
Group
Acute Leukemia Working Party (ALWP)
1st listed author
Ali Bazarbachi
Journal
Hemasphere.
2025
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic

Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Jordi Esteve

Journal

Am J Hematol.

See the full list of the ALWP 2025 publications



Indicators


	2023	2024	2025
Impact factor	277.60	228.00	**210.60**
Oral presentations	23	27	**15**
Poster presentations	22	25	**31**
Educational events	2	1	**3**

Major educational events



Event

51st Annual Meeting of the EBMT



Event

Acute Leukaemia and Cellular Therapy and Immunobiology Working Parties Joint Transplant Programme Track at the 8th Annual Meeting of the IACH

Oct 09, 2025 - Oct 11, 2025 / Paris, France
Discover more

Harmonisation Workshop ALWP - 29-30 September 2025

VISIT THE ALWP WEBPAGE